Is This Stock a Screaming Buy: Bio-Rad Laboratories, Inc. (NYSE:BIO)

Equity Research firms currently have a positive stance on shares of Bio-Rad Laboratories, Inc. (NYSE:BIO). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.00. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $225.00 on a short term basis.

At the time of writing, the stock was trading at $162.80. This represents a change from the opening price of 0.82%. In terms of performance, year to date, the stock is 16.26%. The monthly stock performance comes in at 1.18%. For the quarter, shares are performing at 12.09%. Weekly performance analysis shows the equity at -0.47%.

In taking a look at technical levels, shares are trading 4.71% away from the 50 day simple moving average and 14.35% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -1.26% away from it’s 52- week high and 33.41% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Bio-Rad Laboratories, Inc.’s RSI stands at 60.36. In looking at volatility levels, the shares saw weekly volatility of 1.63% and 1.53% over the past month.

Leave a Comment